Home Bristol-Meyers Squibb Bad News for BMS Drug Opdivo Which Falters During Late Stage Lung...

Bad News for BMS Drug Opdivo Which Falters During Late Stage Lung Cancer Study

299
0

Investment publication Seeking Alpha, reports that Bristol-Myers Squibb’s Opdivo (nivolumab) failed to meet primary end point. The American-based global pharmaceutical company was evaluating Opdivo vs. standard of care (topotecan or amrubicin) in patients with relapsed small cell lung cancer. See the article for more details.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.